Tirzepatide, a GLP-1 and GIP receptor coagonist, was also approved for treating T2D and obesity
The role of GLP-1R in DM is principally to regulate glycemic control by stimulating insulin secretion, inhibiting glucagon secretion, and improving insulin signaling, thereby reducing blood glucose levels
Most patients find that any initial discomfort is manageable and improves significantly after the first 12 weeks, with the therapeutic benefits becoming more apparent over the following months
Movement supports sleep, digestion, and mood without demanding a huge fuel budget
Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset alzheimer's disease
GLP-1 is not really physiologically essential for body weight but pharmacologically, has changed the field of obesity, said Daniel Drucker, a senior scientist at the Lunefield-Tanenbaum Research Institute who researches treatments for type 2 diabetes but was not affiliated with the new study
